Do you want to read an article? Please log in or register.
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma
Further Publications
Related content
Skin Cancer
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
Lancet Oncol.
Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, Schadendorf D, Guminski A, Hauschild A, Wong DJ, Daniels GA, Berking C, Jankovic V, Stankevich E, Booth J, Li S, Weinreich DM, Yancopoulos GD, Lowy I, Fury MG, Rischin D
doi: 10.1016/S1470-2045(19)30728-4.
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
N Engl J Med.
Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG
doi: 10.1056/NEJMoa1805131.
Gastrointestinal Cancer
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Lancet Oncol.
Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, Lin L, Gu K, Liu Y, Ba Y, Miao Z, Jiang X, Zeng M, Chen J, Fu Z, Gan L, Wang J, Zhan X, Liu T, Li Z, Shen L, Shu Y, Zhang T, Yang Q, Zou J, ESCORT Study Group
doi: 10.
Skin Cancer
Incidence of Multiple vs First Cutaneous Squamous Cell Carcinoma on a Nationwide Scale and Estimation of Future Incidences of Cutaneous Squamous Cell Carcinoma
JAMA Dermatol.
Tokez S, Hollestein L, Louwman M, Nijsten T, Wakkee M
doi: 10.1001/jamadermatol.2020.3677.
Skin Cancer
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 Study): an open-label, nonrandomized, multicenter, phase 2 trial
Ann Oncol
Hughes BGM, Munoz-Couselo E, Mortier L, Bratland Å, Gutzmer R, Roshdy O, Mendoza RG, Schachter J, Arance A, Grange F, Meyer N, Joshi A, Billan S, Zhang P, Gumuscu B, Swaby RF, Grob JJ
doi: 10.1016/j.annonc.2021.07.008
SPECIAL REPORT
Skin Cancer
Bavencio® (Avelumab): Treatment for Metastatic Merkel Cell Carcinoma1,2
Head and Neck Cancer
Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base
Cancer.
Zumsteg ZS, Luu M, Yoshida EJ, Kim S, Tighiouart M, David JM, Shiao SL, Mita AC, Scher KS, Sherman EJ, Lee NY, Ho AS
doi: 10.1002/cncr.30933.
Head and Neck CancerFurther Publications
Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)
Eur J Cancer.
Tao Y, Aupérin A, Sun X, Sire C, Martin L, Coutte A, Lafond C, Miroir J, Liem X, Rolland F, Even C, Nguyen F, Saada E, Maillard A, Colin-Batailhou N, Thariat J, Guigay J, Bourhis J
doi: 10.1016/j.ejca.2020.09.008.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Target Oncol
Chouaid C, Filleron T, Debieuvre D, Pérol M, Girard N, Dansin E, Lena H, Gervais R, Cousin S, Otto J, Schott R, Planchard D, Madroszyk A, Kaderbhai C, Dubray-Longeras P, Hiret S, Pichon E, Clément-Duchêne C, Chenuc G, Simon G, Bosquet L, QUantin X
doi: 10.1007/s11523-021-00848-9